Contrarius Investment Management released its third-quarter investor letter for the “Contrarius Global Equity Fund”, reporting a 30.9% return for its investor class in the September quarter. The fund’s performance outperformed the benchmark MSCI World Index, which had a return of 7.3%. The fund’s investment philosophy is independent of benchmark considerations.

In its investor letter, Contrarius Global Equity Fund highlighted Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company focused on precision genetic medicines. Beam Therapeutics Inc. (BEAM) saw a one-month return of 19.13% and gained 12.26% over the last 52 weeks. As of December 29, 2025, BEAM stock closed at $27.84 per share with a market capitalization of $2.83 billion.

Contrarius Global Equity Fund mentioned significant scientific breakthroughs by Beam Therapeutics Inc. (NASDAQ: BEAM) in its third quarter 2025 investor letter. Beam holds patents for ‘base editing’ or CRISPR 2.0 technology. However, BEAM is not among the 30 most popular stocks among hedge funds, with 27 hedge funds holding it at the end of the third quarter.

Beam Therapeutics Inc. (NASDAQ: BEAM) may not be a top pick among hedge funds, but it remains a promising investment. The company’s innovative gene-editing technology has potential, although certain AI stocks are considered to offer greater upside potential with less downside risk. For investors seeking undervalued AI stocks, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock?